Vir Combination is a Oral Liquid in the Human Otc Drug category. It is labeled and distributed by Deseret Biologicals, Inc.. The primary component is Hepatitis B Virus; Human Adenovirus B Serotype 7 Strain 55142 Antigen; Human Adenovirus E Serotype 4 Strain Cl-68578 Antigen; Human Herpesvirus 1; Human Herpesvirus 2; Human Herpesvirus 4; Human Herpesvirus 5; Human Herpesvirus 6; Influenza A Virus A/tasmania/503/2020 Ivr-221 (h3n2) Antigen (formaldehyde Inactivated); Influenza A Virus A/victoria/2570/2019 Ivr-215 (h1n1) Antigen (formaldehyde Inactivated); Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated); Influenza B Virus B/washington/02/2019 Antigen (formaldehyde Inactivated).
| Product ID | 43742-2040_730cbe69-d67d-4041-bb71-46cc2829bcda |
| NDC | 43742-2040 |
| Product Type | Human Otc Drug |
| Proprietary Name | Vir Combination |
| Generic Name | Influenzinum (2021-2022), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6a, Human Herpesvirus 6b, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-barr Virus Nosode |
| Dosage Form | Liquid |
| Route of Administration | ORAL |
| Marketing Start Date | 2022-02-02 |
| Marketing End Date | 2027-08-23 |
| Marketing Category | UNAPPROVED HOMEOPATHIC / |
| Labeler Name | Deseret Biologicals, Inc. |
| Substance Name | HEPATITIS B VIRUS; HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142 ANTIGEN; HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 6; INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (FORMALDEHYDE INACTIVATED); INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (FORMALDEHYDE INACTIVATED) |
| Active Ingredient Strength | 33 [hp_X]/mL; [hp_C]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_C]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL; [hp_X]/mL |
| Pharm Classes | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Live Human Adenovirus Type 4 Vaccine [EPC], Live Human Adenovirus Type 7 Vaccine [EPC], Vaccines, Adenovirus [Chemical/Ingredient], Vaccines, Adenovirus [Chemical/Ingredient], Vaccines, Live, Unattenuated [Chemical/Ingredient], Vaccines, Live, Unattenuated [Chemical/Ingredient] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2022-02-02 |
| Marketing End Date | 2027-08-23 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 43742-2022 | VIR Combination | Influenzinum (2019-2020), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode |
| 43742-2036 | Vir Combination | Influenzinum (2020-2021), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode |
| 43742-2040 | Vir Combination | Influenzinum (2021-2022), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode |
| 43742-2062 | Vir Combination | Influenzinum (2022-2023), Herpes Simplex 1 Nosode, Herpes Simplex 2 Nosode, Human Herpesvirus 6A, Human Herpesvirus 6B, Cytomegalovirus Nosode, Hepatitis B Nosode, Adenoviren Nosode, Epstein-Barr Virus Nosode |